U.S. FDA Approves Bristol Myers Squibb’s Sotyktu® (deucravacitinib) for Treatment of Adults with Psoriatic Arthritis
On Mar. 6, 2026, Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has approved…
Rheumatology
On Mar. 6, 2026, Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has approved…